Developing and commercializing continuous automated blood analyte monitoring devices for ICU.
Location: United States, California, Hayward
Total raised: $25M
Investors 4
| Date | Name | Website |
| - | Mitsui Glo... | mitsui-glo... |
| - | Ascension ... | ascensionv... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Signet Hea... | signetheal... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.03.2019 | Series E | $20M | - |
| 01.11.2012 | - | $5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.03.2019 | OptiScan Biomedical Completes $20M Series E Financing | OptiScan Biomedical Corporation, a Hayward, Calif.-based developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU), closed a $20m Series E financing. The company intends to use the funds for ... |
| 20.03.2019 | OptiScan Biomedical Nabs $20M for FDA-Cleared Continuous Glucose Bedside Monitor for ICU | OptiScan Biomedical, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU) has raised $20 million in Series E funding. The company plans to use the funding to support the commercializat... |
| 01.11.2012 | Developer of automated, bedside glucose monitoring system in the ICU raises $5M | The OptiScanner obtained the CE Mark in September 2011 and a news release from March shows that the company was preparing for a commercial launch in Europe. The product is not available in the U.S. Promoted Telemedicine’s potential to provi... |
| - | Developer of automated, bedside glucose monitoring system in the ICU raises $5M | A California medical device company developing an automated glucose monitoring system for critically ill patients in the intensive care unit raised $5 million, according to two regulatory filings in October. OptiScan Biomedical, based in Ha... |